{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:01:00Z","timestamp":1756166460122,"version":"3.44.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by abnormal megakaryocyte proliferation and a markedly elevated platelet count, which predisposes patients to thrombotic or hemorrhagic events. Approximately 50%\u201360% of ET patients harbor a JAK2 V617F mutation. This mutation drives constitutive JAK kinase activation, promoting megakaryocyte proliferation and platelet production, while potentially activating inflammatory pathways and damaging vascular endothelium. We report a case of a JAK2 V617F-positive ET patient (sporadic presentation) who successfully underwent carotid artery stenting (CAS) for symptomatic internal carotid artery (ICA) stenosis. A 66-year-old male with known JAK2 V617F-positive ET presented with transient slurred speech and right-sided facial droop with mouth deviation. Magnetic resonance imaging\/magnetic resonance angiography (MRI\/MRA) revealed an acute cerebral infarction in the right basal ganglia and corona radiata, along with right ICA stenosis. Aggressive perioperative platelet and inflammation control, employing hydroxyurea, aspirin, and ticagrelor, was instrumental in mitigating the heightened thrombosis risk associated with the JAK2 V617F mutation. This case underscores that ET patients with the JAK2 V617F mutation face a substantial risk of thrombotic recurrence. It highlights the critical importance of rigorous preoperative platelet control, personalized antiplatelet therapy guided by pharmacogenomic principles, and multidisciplinary management in high-risk ET patients undergoing CAS.<\/jats:p>","DOI":"10.3389\/fcvm.2025.1658456","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:27:00Z","timestamp":1756099620000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Minghui","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinbao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.1161\/01.STR.0000174193.89864.55","article-title":"Moyamoya syndrome in an adolescent with essential thrombocythemia: successful intracranial carotid stent placement","volume":"36","author":"Kornblihtt","year":"2005","journal-title":"Stroke"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1182\/bloodadvances.2023010588","article-title":"JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study","volume":"7","author":"Kristiansen","year":"2023","journal-title":"Blood Adv"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2008.004234","article-title":"Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study","volume":"94","author":"Girodon","year":"2009","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ajh.24320","article-title":"Refining prognostication of thrombosis in ET","volume":"91","author":"Barbui","year":"2016","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential thrombocythemia","volume":"381","author":"Tefferi","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-023-00972-x","article-title":"One thousand patients with essential thrombocythemia: the Mayo Clinic experience","volume":"14","author":"Gangat","year":"2024","journal-title":"Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-023-00968-7","article-title":"One thousand patients with essential thrombocythemia: the Florence-CRIMM experience","volume":"14","author":"Loscocco","year":"2024","journal-title":"Blood Cancer J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1182\/bloodadvances.2022007023","article-title":"1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events","volume":"6","author":"Gangat","year":"2022","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1658456\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:27:01Z","timestamp":1756099621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1658456\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":19,"alternative-id":["10.3389\/fcvm.2025.1658456"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1658456","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"article-number":"1658456"}}